Cell Therapy News Volume 23.37 | Oct 31 2022

    By
    Bob
    -
    0
    64








    2022-10-31 | CTN 23.37


    Cell Therapy News by STEMCELL Technologies
    Vol. 23.37 – 31 October, 2022
    TOP STORY

    Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety

    Scientists designed B7-H3-specific CAR T cells, confirmed their preclinical efficacy, and opened BrainChild-03, a first-in-human Phase I trial employing repeated locoregional B7-H3CARs to children with recurrent/refractory central nervous system tumors and diffuse intrinsic pontine glioma.
    [Cancer Discovery]

    Abstract
    Win an award toward an upcoming cell or gene therapy conference
    PUBLICATIONSRanked by the impact factor of the journal

    Therapeutic Gene Editing of T Cells to Correct CTLA-4 Insufficiency

    Investigators designed a homology-directed repair gene editing strategy that inserted the CTLA-4 cDNA into the first intron of the CTLA-4 genomic locus in primary human T cells.
    [Science Translational Medicine]

    Abstract

    Ganglioside-Functionalized Nanoparticles for Chimeric Antigen Receptor T Cell Activation at the Immunological Synapse

    Researchers demonstrated that CAR ligand functionalized, lipid-coated, biodegradable polymer nanoparticles that contained the ganglioside GM3 binded to CD169-expressing antigen presenting cells (APCs) and localized to the cell contact site between APCs and CAR T cells upon initiation of cell conjugates.
    [ACS Nano]

    AbstractGraphical Abstract

    Remodeling of Tumor Microenvironment by Microwave Ablation Potentiates Immunotherapy of AXL-Specific CAR T Cells against Non-Small Cell Lung Cancer

    Scientists showed that AXL, which was highly expressed in non-small cell lung cancer but not in normal tissues, might be a target for CAR T cell therapy.
    [Nature Communications]

    Full Article

    Outcome of Chimeric Antigen Receptor T Cell Therapy Following Treatment with Inotuzumab Ozogamicin in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

    The authors investigated whether prior use of inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, may impact CAR T-cell manufacturing or efficacy via pre-CART-19 depletion of the B cell compartment.
    [Leukemia]

    Abstract

    Competency of iPSC-Derived Retinas in MHC-Mismatched Transplantation in Non-Human Primates

    Researchers studied the immunological features of induced pluripotent stem cell (iPSC)-retina transplantation using major histocompatibility complex (MHC)-homozygote monkey iPSC-retinas in monkeys with laser-induced retinal degeneration in MHC-matched and -mismatched transplantation.
    [Stem Cell Reports]

    Full ArticleGraphical Abstract

    hUMSCs Transplantation Regulates AMPK/NR4A1 Signaling Axis to Inhibit Ovarian Fibrosis in POI Rats

    The authors investigated the signal axis mechanism that was involved in the ovarian function recovery of premature ovarian insufficiency (POI) rats following human umbilical cord mesenchymal stem cells (hUMSCs) transplantation.
    [Stem Cell Reviews and Reports]

    AbstractGraphical Abstract

    Transplantation of Human Adipose-Derived Stem Cells Overexpressing LIF/IFN-β Promotes Recovery in Experimental Autoimmune Encephalomyelitis (EAE)

    Investigators evaluated the effects of co-overexpressing beta interferon (IFN-β) and Leukemia inhibitory factor (LIF) in human adipose-derived stem cells on the experimental autoimmune encephalomyelitis.
    [Scientific Reports]

    Full Article

    Hepatocyte Transplantation Rebalances Cytokines for Hepatic Regeneration in Rats with ATM Pathway-Related Acute Liver Failure

    Hepatocyte transplantation increased candidate cytokine levels, leading to Atm, Stat3, and Akt signaling in hepatocytes and nonparenchymal cells, lowering of inflammation, improvements in intermediary metabolism, DNA repair, and hepatocyte proliferation.
    [American Journal of Pathology]

    Abstract

    Explore this validated protocol for high-efficiency gene editing of Human Pluripotent Stem Cells using the ArciTectâ„¢ CRISPR-Cas9 System.
    REVIEWS

    Tumor Buster – Where Will the CAR-T Cell Therapy ‘Missile’ Go?

    The authors summarize CAR-T cell therapies’ clinical trials, applications, research frontiers, and limitations in treating different cancers.
    [Molecular Cancer]

    Full Article
    INDUSTRY AND POLICY NEWS

    Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models

    Candel Therapeutics, Inc. announced a collaboration with the University of Pennsylvania (Penn) to study the impact of novel viral immunotherapies based on Candel’s proprietary enLIGHTEN™ Discovery Platform to strengthen the effects of Penn’s CAR-T cell therapies in solid tumor models.
    [Candel Therapeutics, Inc.]

    Press Release

    2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-Based Immunotherapies

    2seventy bio, Inc. and JW Therapeutics announced a strategic alliance to establish a translational and clinical cell therapy development platform designed to more rapidly explore T cell-based immunotherapy therapy products in the Chinese mainland, Hong Kong, and Macao.
    [2seventy bio, Inc.]

    Press Release
    FEATURED EVENT

    AACR Special Conference: Cancer Metastasis

    November 14 – 17, 2022
    Portland, Oregon, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Associate – Therapy-Resistance of Human Cancers

    Baylor College of Medicine – Houston, Texas, United States

    Research Fellow – T Cell Engineering and Immunotherapy

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Assistant Professor – Immunotherapy and Cellular Therapies

    The University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Research Associate – Aplastic Anaemia Pathophysiology

    King’s College London – London, England, United Kingdom

    Clinical Director – Department of Health and Human Services

    NCI – Bethesda, Maryland, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter